Cochrane Central Register of Controlled Trials (CENTRAL)

Searched 3 October 2017 [1477 records]
Searched 12 March 2019 [114 new records]
Searched 16 February 2021 [147 new records]

#1[mh "attention deficit and disruptive behavior disorders"]
#2[mh "attention deficit disorder with hyperactivity"]
#3[mh "conduct disorder"]
#4ADHD or ADHS or ADDH or AD next HD or HKD or TDAH
#5((attention* or behav*) near/3 (defic* or dysfunc* or disorder*))
#6((disrupt* near/3 disorder*) or (disrupt* near/3 behav*) or (defian* near/3 disorder*) or (defian* near/3 behav*))
#7(impulsiv* or inattentiv* or inattention*)
#8[mh hyperkinesis]
#9(hyperkin* or hyper‐kin* or hkd)
#10(minimal near/3 brain near/3 (disorder* or dysfunct* or damage*))
#11(hyperactiv* or hyper‐activ*)
#12{or #1‐#11}
#13[mh methylphenidate]
#14(Adaphen* or Aptensio* or Aradix* or Attenade* or Biphentin* or Calocain* or Centedrin* or Concerta* or Conmet* or Daytrana* or Dexmethylphenidat* or Difumenil* or D‐methylphenidat* or Equasym* or Fenilidato* or Focalin* or Matoride* or Medicebran* or Medikid* or Medikinet* or Meridil* or Metadate* or Methylphenidylacetat* or methyl NEXT phenidylacetat* or Methylofenidan* or Methylin* or Methypatch or methylphenidat* or Metilfenidato* or Phenidylate or Phenidyl hydrochlorid* or Phenidylhydrochlorid* or Quillivant* or Richter Works or Riphenidat* or Ritalin* or Ritrocel* or Rubifen* or Tsentedrin*)
#15#13 or #14
#16    #12 and #15 in Trials    
#17    #12 and #15 with Publication Year from 2017 to 2019, in Trials   
#18    #12 and #15 with Publication Year from 2019 to 2021, in Trials    

MEDLINE Ovid

Searched 3 October 2017 [1467 records]
Searched 12 March 2019 [97 new records]
Searched 15 February 2021 [99 new records]

1 "attention deficit and disruptive behavior disorders"/
2 attention deficit disorder with hyperactivity/
3 conduct disorder/
4 ADHD.tw,kf.
5 ADHS.tw,kf.
6 ADDH.tw,kf.
7 ("AD/HD" or hkd).tw,kf.
8 TDAH.tw,kf.
9 ((attention$ or behav$) adj3 (defic$ or dysfunc$ or disorder$)).tw,kf. (49848)
10 ((disrupt$ adj3 disorder$) or (disrupt$ adj3 behav$) or (defian$ adj3 disorder$) or (defian$ adj3 behav$)).tw,kf
11 (impulsiv$ or inattentiv$ or inattention$).tw,kf.
12 hyperkinesis/
13 (hyperkin$ or hyper‐kin$).tw,kf. (4266)
14 (minimal adj3 brain adj3 (disorder$ or dysfunct$ or damage$)).tw,kf.
15 (hyperactiv$ or hyper‐activ$).tw,kf.
16 or/1‐15
17 exp Methylphenidate/
18 Adaphen$.mp.
19 Aptensio$.mp.
20 Aradix$.mp.
21 Attenade$.mp.
22 Biphentin$.mp.
23 Calocain$.mp.
24 Centedrin$.mp.
25 Concerta$.mp.
26 Conmet$.mp.
27 Daytrana$.mp.
28 Dexmethylphenidat$.mp.
29 Difumenil$.mp.
30 D‐methylphenidat$.mp.
31 Equasym$.mp.
32 Fenilidato$.mp.
33 Focalin$.mp.
34 Matoride$.mp.
35 Medicebran$.mp.
36 Medikid$.mp.
37 Medikinet$.mp.
38 Meridil$.mp.
39 Metadate$.mp.
40 (Methylphenidylacetat$ or methyl phenidylacetat$).mp.
41 Methylofenidan$.mp.
42 Methylin$.mp.
43 Methypatch.mp.
45 Metilfenidato$.mp.
44 methylphenidat$.mp.
46 Novo‐Methylphenidat$.mp.
47 Phenidylate.mp.
48 (Phenidyl hydrochlorid$ or Phenidylhydrochlorid$).mp.
49 Quillivant$.mp.
50 Richter Works.mp.
51 Riphenidat$.mp.
52 Ritalin$.mp.
53 Ritrocel$.mp.
54 Rubifen$.mp.
55 Tsentedrin$.mp.
56 or/17‐55
57 16 and 56
58 randomized controlled trial.pt.
59 controlled clinical trial.pt.
60 randomized.ab.~
61 placebo.ab.
62 clinical trials as topic.sh.
63 randomly.ab.
64 trial.ti.
65 or/58‐64
66 exp animals/ not humans.sh.
67 65 not 66
68 57 and 67
69 (201710* or 201711* or 201712* or 2018* or 2019* ).dt,ez,da,ed.70  68 and 69
71  (201902* or 201903* or 201904* or 201905* or 201906* or 201907* or 201908* or 201909* or 201910* or 201911* or 201912* or 2020* or 2021*).dt,ez,da,ed. 
72     68 and 70 

MEDLINE In_Process and Other Non‐indexed Citations OVID

Searched 3 October 2017 [126 records]
Searched 13 March 2019 [66 new records]
Searched 15 February 2021 [53 new records]

1 ADHD.tw,kf.
2 ADHS.tw,kf.
3 ADDH.tw,kf.
4 ("AD/HD" or hkd).tw,kf.
5 TDAH.tw,kf.
6 ((attention$ or behav$) adj3 (defic$ or dysfunc$ or disorder$)).tw,kf.
7 ((disrupt$ adj3 disorder$) or (disrupt$ adj3 behav$) or (defian$ adj3 disorder$) or (defian$ adj3 behav$)).tw,kf.
8 (impulsiv$ or inattentiv$ or inattention$).tw,kf.
9 (hyperkin$ or hyper‐kin$).tw,kf.
10 (minimal adj3 brain adj3 (disorder$ or dysfunct$ or damage$)).tw,kf.
11 (hyperactiv$ or hyper‐activ$).tw,kf.
12 or/1‐11
13 Adaphen$.mp.
14 Aptensio$.mp.
15 Aradix$.mp.
16 Attenade$.mp.
17 Biphentin$.mp.
18 Calocain$.mp.
19 Centedrin$.mp.
20 Concerta$.mp.
21 Conmet$.mp.
22 Daytrana$.mp.
23 Dexmethylphenidat$.mp.
24 Difumenil$.mp.
25 D‐methylphenidat$.mp.
26 Equasym$.mp.
27 Fenilidato$.mp.
28 Focalin$.mp.
29 Matoride$.mp.
30 Medicebran$.mp.
31 Medikid$.mp.
32 Medikinet$.mp.
33 Meridil$.mp.
34 Metadate$.mp.
35 (Methylphenidylacetat$ or methyl phenidylacetat$).mp.
36 Methylofenidan$.mp.
37 Methylin$.mp.
38 Methypatch.mp.
39 methylphenidat$.mp.
40 Metilfenidato$.mp.
41 Novo‐Methylphenidat$.mp.
42 Phenidylate.mp.
43 (Phenidyl hydrochlorid$ or Phenidylhydrochlorid$).mp.
44 Quillivant$.mp.
45 Richter Works.mp.
46 Riphenidat$.mp.
47 Ritalin$.mp.
48 Ritrocel$.mp.
49 Rubifen$.mp.
50 Tsentedrin$.mp.
51 or/13‐50
52 random$.tw,kf.
53 placebo.ab.
54 trial.ti.
55 RCT.tw,kf.
56 or/52‐55
57 12 and 51 and 56

MEDLINE E‐Pub Ahead of Print (OVID)

Searched 3 October 2017 [27 records]
Searched 13 March 2019 [13 new records]
Searched 15 February 2021 [22 new records]

1 ADHD.tw,kf.
2 ADHS.tw,kf.
3 ADDH.tw,kf.
4 ("AD/HD" or hkd).tw,kf.
5 TDAH.tw,kf.
6 ((attention$ or behav$) adj3 (defic$ or dysfunc$ or disorder$)).tw,kf.
7 ((disrupt$ adj3 disorder$) or (disrupt$ adj3 behav$) or (defian$ adj3 disorder$) or (defian$ adj3 behav$)).tw,kf.
8 (impulsiv$ or inattentiv$ or inattention$).tw,kf.
9 (hyperkin$ or hyper‐kin$).tw,kf
10 (minimal adj3 brain adj3 (disorder$ or dysfunct$ or damage$)).tw,kf.
11 (hyperactiv$ or hyper‐activ$).tw,kf.
12 or/1‐11
13 Adaphen$.mp.
14 Aptensio$.mp.
15 Aradix$.mp.
16 Attenade$.mp.
17 Biphentin$.mp.
18 Calocain$.mp.
19 Centedrin$.mp.
20 Concerta$.mp.
21 Conmet$.mp.
22 Daytrana$.mp.
23 Dexmethylphenidat$.mp.
24 Difumenil$.mp.
25 D‐methylphenidat$.mp.
26 Equasym$.mp.
27 Fenilidato$.mp.
28 Focalin$.mp.
29 Matoride$.mp.
30 Medicebran$.mp.
31 Medikid$.mp.
32 Medikinet$.mp.
33 Meridil$.mp.
34 Metadate$.mp.
35 (Methylphenidylacetat$ or methyl phenidylacetat$).mp.
36 Methylofenidan$.mp.
37 Methylin$.mp.
38 Methypatch.mp.
39 methylphenidat$.mp.
40 Metilfenidato$.mp.
41 Novo‐Methylphenidat$.mp.
42 Phenidylate.mp.
43 (Phenidyl hydrochlorid$ or Phenidylhydrochlorid$).mp.
44 Quillivant$.mp.
45 Richter Works.mp.
46 Riphenidat$.mp.
47 Ritalin$.mp.
48 Ritrocel$.mp.
49 Rubifen$.mp.
50 Tsentedrin$.mp.
51 or/13‐50
52 random$.tw,kf.
53 placebo.ab.
54 trial.ti.
55 RCT.tw,kf.
56 or/52‐55
57 12 and 51 and 56

Embase Ovid strategy up to 2019

Searched 2 October 2017 [2687 records]
Searched 15 March 2019 [187 new records]

1 attention deficit disorder/
2 hyperactivity/
3 conduct disorder/
4 ADHD.tw,kw.
5 ADDH.tw,kw.
6 ADHS.tw,kw.
7 ("AD/HD" or HKD).tw,kw.
8 TDAH.tw,kw.
9 ((attention$ or behav$) adj3 (defic$ or dysfunc$ or disorder$)).tw,kw.
10 ((disrupt$ adj3 disorder$) or (disrupt$ adj3 behav$) or (defian$ adj3 disorder$) or (defian$ adj3 behav$)).tw,kw.
11 (impulsiv$ or inattentiv$ or inattention$).tw,kw.
12 hyperkinesis/
13 (hyperkin$ or hyper‐kin$ or hkd).tw,kw.
14 (minimal adj3 brain adj3 (disorder$ or dysfunct$ or damage$)).tw.
15 (hyperactiv$ or hyper‐activ$).tw.
16 or/1‐15
17 methylphenidate/
18 (Adaphen$ or Aptensio$ or Aradix$ or Attenade$ or Biphentin$).mp.
19 methylphenidate/
20 (Adaphen$ or Aptensio$ or Aradix$ or Attenade$ or Biphentin$ or Calocain$ or Centedrin$ or Concerta$ or Conmet$ or Daytrana$ or Dexmethylphenidat$ or Difumenil$ or D‐methylphenidat$ or Equasym$ or Fenilidato$ or Focalin$ or Matoride$ or Medicebran$ or Medikid$ or Medikinet$ or Meridil$ or Metadate$ or Methylphenidylacetat$ or methyl phenidylacetat$ or Methylofenidan$ or Methylin$ or Methypatch or methylphenidat$ or Metilfenidato$ or Phenidylate or Phenidyl hydrochlorid$ or Phenidylhydrochlorid$ or Quillivant$ or Ritcher Works or Riphenidat$ or Ritalin$ or Ritrocel$ or Rubifen$ or Tsentedrin$).mp.
21 19 or 20
22 16 and 21
23 limit 22 to "therapy (best balance of sensitivity and specificity)"
24 remove duplicates from 23
25 limit 24 to yr="2017 ‐Current"

Embase Ovid Strategy 2021 

Searched 15 February 2021 [271 new records]
1     attention deficit disorder/ 
2     hyperactivity/ 
3     conduct disorder/ 
4     ADHD.tw,kw. 
5     ADDH.tw,kw. 
6     ADHS.tw,kw. 
7     ("AD/HD" or HKD).tw,kw. 
8     TDAH.tw,kw. 
9     ((attention$ or behav$) adj3 (defic$ or dysfunc$ or disorder$)).tw,kw.
10     ((disrupt$ adj3 disorder$) or (disrupt$ adj3 behav$) or (defian$ adj3 disorder$) or (defian$ adj3 behav$)).tw,kw.
11     (impulsiv$ or inattentiv$ or inattention$).tw,kw. 
12     hyperkinesis/ 
13     (hyperkin$ or hyper‐kin$ or hkd).tw,kw. 
14     (minimal adj3 brain adj3 (disorder$ or dysfunct$ or damage$)).tw,kw. 
15     (hyperactiv$ or hyper‐activ$).tw,kw. 
16     or/1‐15 
17     methylphenidate/ 
18     (Adaphen$ or Aptensio$ or Aradix$ or Attenade$ or Biphentin$).mp. 
19     methylphenidate/ 
20     (Adaphen$ or Aptensio$ or Aradix$ or Attenade$ or Biphentin$ or Calocain$ or Centedrin$ or Concerta$ or Conmet$ or Daytrana$ or Dexmethylphenidat$ or Difumenil$ or D‐methylphenidat$ or Equasym$ or Fenilidato$ or Focalin$ or Matoride$ or Medicebran$ or Medikid$ or Medikinet$ or Meridil$ or Metadate$ or Methylphenidylacetat$ or methyl phenidylacetat$ or Methylofenidan$ or Methylin$ or Methypatch or methylphenidat$ or Metilfenidato$ or Phenidylate or Phenidyl hydrochlorid$ or Phenidylhydrochlorid$ or Quillivant$ or Ritcher Works or Riphenidat$ or Ritalin$ or Ritrocel$ or Rubifen$ or Tsentedrin$).mp. 
21     19 or 20 
22     16 and 21 (
23     Randomized controlled trial/ 
24     Controlled clinical study/ 
25     random$.ti,ab. 
26     randomization/
27     intermethod comparison/ 
28     placebo.ti,ab. 
29     (compare or compared or comparison).ti.
30     ((evaluated or evaluate or evaluating or assessed or assess) and (compare or compared or comparing or comparison)).ab. 
31     (open adj label).ti,ab. 
32     ((double or single or doubly or singly) adj (blind or blinded or blindly)).ti,ab. 
33     double blind procedure/ 
34     parallel group$1.ti,ab. 
35     (crossover or cross over).ti,ab.
36     ((assign$ or match or matched or allocation) adj5 (alternate or group$1 or intervention$1 or patient$1 or subject$1 or participant$1)).ti,ab. (
37     (assigned or allocated).ti,ab. 
38     (controlled adj7 (study or design or trial)).ti,ab.
39     (volunteer or volunteers).ti,ab. 
40     human experiment/
41     trial.ti. 
42     or/23‐41 
43     (random$ adj sampl$ adj7 ("cross section$" or questionnaire$1 or survey$ or database$1)).ti,ab. not (comparative study/ or controlled study/ or randomi?ed controlled.ti,ab. or randomly assigned.ti,ab.) 
44     Cross‐sectional study/ not (randomized controlled trial/ or controlled clinical study/ or controlled study/ or randomi?ed controlled.ti,ab. or control group$1.ti,ab.) 
45     (((case adj control$) and random$) not randomi?ed controlled).ti,ab. 
46     (Systematic review not (trial or study)).ti. 
47     (nonrandom$ not random$).ti,ab. 
48     "Random field$".ti,ab. 
49     (random cluster adj3 sampl$).ti,ab. 
50     (review.ab. and review.pt.) not trial.ti. 
51     "we searched".ab. and (review.ti. or review.pt.)
52     "update review".ab. 
53     (databases adj4 searched).ab. 
54     (rat or rats or mouse or mice or swine or porcine or murine or sheep or lambs or pigs or piglets or rabbit or rabbits or cat or cats or dog or dogs or cattle or bovine or monkey or monkeys or trout or marmoset$1).ti. and animal experiment/ 
55     Animal experiment/ not (human experiment/ or human/) 
56     or/43‐55 
57     42 not 56
58     22 and 57 
59     limit 58 to yr="2019 ‐Current" 

PsycINFO Ovid

Searched 3 October 2017 [1339 records]
Searched 13 March 2019 [74 new records]
Searched 15 February 2021 [136 new records]

1 exp attention deficit disorder/
2 exp Behavior Problems/
3 adhd.tw.
4 addh.tw.
5 adhs.tw.
6 "ad/hd".tw.
7 TDAH.tw.
8 ((attention$ or behav$) adj3 (defic$ or dysfunc$ or disorder$)).tw.
9 ((disrupt$ adj3 disorder$) or (disrupt$ adj3 behav$) or (defian$ adj3 disorder$) or (defian$ adj3 behav$)).tw.
10 Impulsiveness/
11 (impulsiv$ or inattentiv$ or inattention$).tw.
12 hyperkinesis/
13 (hyperkin$ or hyper‐kin$ or hkd).tw.
14 (minimal adj3 brain$ adj3 (damag$ or disorder$ or dysfunc$)).tw.
15 (hyperactiv$ or hyper‐activ$).tw.
16 or/1‐15
17 methylphenidate/
18 (Adaphen$ or Aptensio$ or Aradix$ or Attenade$ or Biphentin$ or Calocain$ or Centedrin$ or Concerta$ or Conmet$ or Daytrana$ or Dexmethylphenidat$ or Difumenil$ or D‐methylphenidat$ or Equasym$ or Fenilidato$ or Focalin$ or Matoride$ or Medicebran$ or Medikid$ or Medikinet$ or Meridil$ or Metadate$ or Methylphenidylacetat$ or methyl phenidylacetat$ or Methylofenidan$ or Methylin$ or Methypatch or methylphenidat$ or Metilfenidato$ or Phenidylate or Phenidyl hydrochlorid$ or Phenidylhydrochlorid$ or Quillivant$ or Richter Works or Riphenidat$ or Ritalin$ or Ritrocel$ or Rubifen$ or Tsentedrin$).tw,id.
19 17 or 18
20 16 and 19
21 clinical trials/
22 random sampling/
23 placebo/
24 Experiment controls/ (836)
25 ((clinic$ or control$) adj (study or trial$ or experiment$)).tw.
26 ((compar$ or control$ or experiment$ or treat$) adj3 (subjects or group$)).tw.
27 ((singl$ or doubl$ or trebl$ or tripl$) adj3 (blind$ or mask$)).tw.
28 (randomiz$ or randomis$).tw.
29 randomly.tw.
30 exp program evaluation/
31 exp treatment outcomes/
32 exp treatment effectiveness evaluation/
33 ((effectiveness or evaluat$) adj3 (stud$ or research$)).tw.
34     or/21‐33
35 20 and 34
36 limit 35 to up=20190301‐20210208

Cochrane Database of Systematic Reviews (CDSR), in the Cochrane Library

Searched 3 October 2017 [10 records]
Searched 12 March 2019 [5 new records]
Searched 16 February 2021 [1 new record]

#1[mh "attention deficit and disruptive behavior disorders"]
#2[mh "attention deficit disorder with hyperactivity"]
#3(ADHD or ADHS or ADDH or AD next HD or HKD or TDAH):ti,ab,kw
#4((attention* or behav*) near/3 (defic* or dysfunc* or disorder*)):ti,ab,kw
#5(impulsiv* or inattentiv* or inattention*):ti,ab,kw
#6(hyperactiv* or hyper next activ*):ti,ab,kw
#7{or #1‐#6}
#8[mh methylphenidate]
#9(Adaphen* or Aptensio* or Aradix* or Attenade* or Biphentin* or Calocain* or Centedrin* or Concerta* or Conmet* or Daytrana* or Dexmethylphenidat* or Difumenil* or D‐methylphenidat* or Equasym* or Fenilidato* or Focalin* or Matoride* or Medicebran* or Medikid* or Medikinet* or Meridil* or Metadate* or Methylphenidylacetat* or methyl next phenidylacetat* or Methylofenidan* or Methylin* or Methypatch or methylphenidat* or Metilfenidato* or Phenidylate or Phenidyl hydrochlorid* or Phenidylhydrochlorid* or Quillivant* or Richter Works or Riphenidat* or Ritalin* or Ritrocel* or Rubifen* or Tsentedrin*):ti,ab,kw
#10#8 or #9
#11#7 and #10 in Cochrane Reviews, Cochrane Protocols
#12#7 AND #10 with Cochrane Library publication date Between Nov 2017 and Mar 2019, in Cochrane Reviews, Cochrane Protocols    
#13 #7 AND #10 with Cochrane Library publication date Between Mar 2019 and Feb 2021, in Cochrane Reviews, Cochrane Protocols

Database of Abstracts of Reviews of Effects (DARE), in the Cochrane Library

Searched 3 October 2017 [23 records]
Not searched after 2017 as database no longer maintained.

#1[mh "attention deficit and disruptive behavior disorders"]
#2[mh "attention deficit disorder with hyperactivity"]
#3[mh "conduct disorder"]
#4ADHD or ADHS or ADDH or "AD next HD" or HKD or TDAH
#5((attention* or behav*) near/3 (defic* or dysfunc* or disorder*))
#6((disrupt* near/3 disorder*) or (disrupt* near/3 behav*) or (defian* near/3 disorder*) or (defian* near/3 behav*))
#7(impulsiv* or inattentiv* or inattention*)
#8[mh hyperkinesis]
#9(hyperkin* or hyper‐kin* or hkd)
#10(minimal near/3 brain near/3 (disorder* or dysfunct* or damage*))
#11(hyperactiv* or hyper‐activ*)
#12{or #1‐#11}
#13[mh methylphenidate]
#14(Adaphen* or Aptensio* or Aradix* or Attenade* or Biphentin* or Calocain* or Centedrin* or Concerta* or Conmet* or Daytrana* or Dexmethylphenidat* or Difumenil* or D‐methylphenidat* or Equasym* or Fenilidato* or Focalin* or Matoride* or Medicebran* or Medikid* or Medikinet* or Meridil* or Metadate* or Methylphenidylacetat* or methyl phenidylacetat* or Methylofenidan* or Methylin* or Methypatch or methylphenidat* or Metilfenidato* or Phenidylate or Phenidyl hydrochlorid* or Phenidylhydrochlorid* or Quillivant* or Ritcher Works or Riphenidat* or Ritalin* or Ritrocel* or Rubifen* or Tsentedrin*)
#15#13 or #14
#16#12 and #15 in Other Reviews

CINAHL Plus EBSCOhost

Searched 4 October 2017 [634 records]
Searched 15 March 2019 [119 new records]
Searched 16 February 2021 [98 new records]

S1(MH "Attention Deficit Hyperactivity Disorder")
S2ADHD
S3ADDH
S4ADDH
S5ADHS
S6"AD/HD" or HKD OR TDAH
S7((attention* or behav*) n3 (defic* or dysfunc* or disorder*))
S8((disrupt* N3 disorder*) or (disrupt* N3 behav*) or (defian* N3 disorder*) or (defian* N3 behav*))
S9(impulsiv* or inattentiv* or inattention*
S10(MH "Hyperkinesis")
S11hyperkin* or hyper‐kin*)
S12(minimal N3 brain N3 (disorder* or dysfunct* or damage*))
S13hyperactiv* or hyper‐activ*
S14S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S7 OR S8 OR S9 OR S10 OR S11 OR S12 OR S13
S15(MH "Methylphenidate")
S16(Adaphen* or Aptensio* or Aradix* or Attenade* or Biphentin* or Calocain* or Centedrin* or Concerta* or Conmet* or Daytrana* or Dexmethylphenidat* or Difumenil* or D‐methylphenidat* or Equasym* or Fenilidato* or Focalin* or Matoride* or Medicebran* or Medikid* or Medikinet* or Meridil* or Metadate* or Methylphenidylacetat* or methyl phenidylacetat* or Methylofenidan* or Methylin* or Methypatch or methylphenidat* or Metilfenidato* or Phenidylate or Phenidyl hydrochlorid* or Phenidylhydrochlorid* or Quillivant* or Richter Works or Riphenidat* or Ritalin* or Ritrocel* or Rubifen* or Tsentedrin*)
S17S15 OR S16
S18S14 AND S17
S19(MH "Clinical Trials+")
S20MH random assignment
S21(MH "Meta Analysis")
S22(MH "Crossover Design")
S23(MH "Quantitative Studies")
S24PT randomized controlled trial
S25PT Clinical trial
S26(clinical trial*) or (control* N2 trial*)
S27("follow‐up study" or "follow‐up research")
S28(prospectiv* study or prospectiv* research)
S29(MH "Program Evaluation")
S30(MH "Treatment Outcomes")
S31TI(single N2 mask* or single N2 blind*) OR AB(single N2 mask* or single N2 blind*)S32TI((doubl* N2 mask*) or(doubl* N2 blind*)) OR AB((doubl* N2 mask*) or (doubl* N2 blind*))
S33TI ((tripl* N2 mask*) or (tripl* N2 blind*)) or ((trebl* N2 mask*) or (trebl* N2 blind*)) OR AB((tripl* N2 mask*) or (tripl* N2 blind*)) or ((trebl* N2 mask*) or (trebl* N2 blind*)
S34(MH "Evaluation Research+")
S35TI (evaluat* N2 study or evaluat* N2 research) OR AB (evaluat* N2 study or evaluat* N2 research)
S36TI(random* OR RCT) OR AB(random* OR RCT)
S37S19 OR S20 OR S21 OR S22 OR S23 OR S24 OR S25 OR S26 OR S27 OR S28 OR S29 OR S30 OR S31 OR S32 OR S33 OR S34 OR S35 OR S36
S38S18 AND 37

Conference Proceedings Citation Index ‐ Science Web of Science Clarivate

Searched 4 October 2017 [166 records]
Searched 15 March 2019 [5 new records]
Searched 16 February 2021 [4 new records]

# 10 #9 AND #8
Indexes=CPCI‐S Timespan=All years
# 9 TS=(random* OR control* OR RCT* OR placebo* OR blind* or "systematic review" OR "meta analys*s")
Indexes=CPCI‐S Timespan=All years
# 8 #7 AND #6
Indexes=CPCI‐S Timespan=All years
# 7 TS= (Adaphen* or Aptensio* or Aradix* or Attenade* or Biphentin* or Calocain* or Centedrin* or Concerta* or Conmet* or Daytrana* or Dexmethylphenidat* or Difumenil* or "D‐methylphenidat*" or Equasym* or Fenilidato* or Focalin* or Matoride* or Medicebran* or Medikid* or Medikinet* or Meridil* or Metadate* or Methylphenidylacetat* or "methyl phenidylacetat*" or Methylofenidan* or Methylin* or Methypatch or methylphenidat* or Metilfenidato* or Phenidylate or "Phenidyl hydrochlorid*" or Phenidylhydrochlorid* or Quillivant* or "Richter Works" or Riphenidat* or Ritalin* or Ritrocel* or Rubifen* or Tsentedrin*)
Indexes=CPCI‐S Timespan=All years
# 6#5 OR #4 OR #3 OR #2 OR #1
Indexes=CPCI‐S Timespan=All years
# 5 TS=(minimal near/3 brain near/3 (disorder* or dysfunct* or damage*))
Indexes=CPCI‐S Timespan=All years
# 4 TS=(impulsiv* or inattentiv* or inattention* OR hyperkin* or "hyper‐kin*" OR hyperactiv* OR "hyper‐activ*")
Indexes=CPCI‐S Timespan=All years
# 3 TS=((disrupt* near/3 disorder*) or (disrupt* near/3 behav*) or (defian* near/3 disorder*) or (defian* near/3 behav*))
Indexes=CPCI‐S Timespan=All years
# 2 TS=((attention* or behav*) near/3 (defic* or dysfunc* or disorder*))
Indexes=CPCI‐S Timespan=All years
# 1 TS=(ADHD or ADHS or ADDH or "AD HD" or HKD or TDAH)
Indexes=CPCI‐S Timespan=All years

LILACS (Latin American and Caribbean Health Science Information)

Searched 4 October 2017 [19 records]
Searched 15 March 2019 [no new records]
Searched 16 February 2021 [no new records]

(mh:("attention deficit and disruptive behavior disorders" OR "attention deficit disorder with hyperactivity" OR "conduct disorder" OR hyperkinesis)) OR (tw:(adhd OR adhs OR addh OR "AD/HD" OR hkd OR tdah )) OR (tw:("ATTENTION DEFICIT*" OR impulsiv* OR inattentiv* OR inattention* OR hyperactiv* OR hyper‐activ*)) AND (mh:((adaphen* OR aptensio* OR aradix* OR attenade* OR biphentin* OR calocain* OR centedrin* OR concerta* OR conmet* OR daytrana* OR dexmethylphenidat* OR difumenil* OR d‐methylphenidat* OR equasym* OR fenilidato* OR focalin* OR matoride* OR medicebran* OR medikid* OR medikinet* OR meridil* OR metadate* OR methylphenidylacetat* OR methyl phenidylacetat* OR methylofenidan* OR methylin* OR methypatch OR methylphenidat* OR metilfenidato* OR phenidylate OR phenidylhydrochlorid* OR phenidylhydrochlorid* OR quillivant* OR richter works OR riphenidat* OR ritalin* OR ritrocel* OR rubifen* OR tsentedrin*))) AND (instance:"regional") AND ( db:("LILACS") AND type_of_study:("clinical_trials" OR "systematic_reviews"))

ClinicalTrials.gov clinicaltrials.gov/

Searched 4 October 2017 [48]
Searched 15 March 2019 Limited by First posted from 10/05/2017 to 03/15/2019 [4 new records]
Searched 16 February 2021 Limited by First posted from 03/15/2019  to 02/16/2021[22 new records]

LONG ACTING OR DELAYED OR EXTENDED OR PROLONGED OR RELEASE | ADHD OR "ATTENTION DEFICIT" OR HYPERACTIVE | Methylphenidate | Adult

EU Clinical Trials Register www.clinicaltrialsregister.eu/ctr‐search/

Searched 4 October 2017 [28 records]
Searched 15 March 2019 [2 new records]
Searched 16 February 2021 [1 new record]

methylphenidate AND ADHD AND Age Range = ADULT

ISRCTN www.isrctn.com/

Searched 4 October [5 records]
Searched 15 March 2019 [ no new records]
Searched 16 February 2021 [ no new records]

Condition: Attention Deficit Hyperactivity Disorder Interventions: methylphenidate Participant age range: Adult

WHO ICTRP www.who.int/ictrp/en/

Searched 4 October [38 records]
Searched 15 MARCH 2019 limited by date of registration between 05/10/2017 AND 15/03/2019 [5 new records] 
Attempted access 16 March 2021 limited by date of registration between 15/03/2019 AND 16/02/2021 but website unresponsive because of heavy traffic generated by pandemic.

CONDITION ADHD OR "ATTENTION DEFICIT" OR HYPERACTIV*

INTERVENTION methylphenidate AND extended OR methylphenidate AND prolonged OR methylphenidate AND release OR methylphenidate AND Long

Drug regulatory agencies

We included drug regulatory documents that contained data from clinical trials according to our inclusion criteria (Criteria for considering studies for this review). We did not include regulatory documents related to generic drugs or applications that did not include clinical trial data or only reported pharmacokinetic studies or studies in healthy adults.

We searched 12 drug regulatory agency databases (eTable 1). The European Medicines Agency has not approved any methylphenidate formulation, so we also searched the Heads of Medicines Agencies' (HMA) MR Index of approved drugs to identify which National Competent Authorities have approved the drugs in Europe. HMA’s MR Index is a European database of approved pharmaceutical drugs in the European Union across the different National Competent Authorities. The HMA MR Index database is not exhaustive, so we also handsearched all known European drug regulatory agencies' websites and databases of regulatory documents. See overview in eTable 1.

We describe each search string and detailed results in the Excel datafile available from osf.io/39wzk/?view_only=a1d2c58b069c4e99b8c836107e99fcad.

Pharmaceutical company databases

We searched the websites and clinical trial databases of the marketing authorisation holders of extended‐release methylphenidate formulations approved for use in adults: Novartis (Ritalin LA, Ritalin SR and Focalin XL), Janssen (Concerta), Medice (Medikinet) and Purdue (Foquest/Adhansia).

eTable 2. ClinicalTrials.gov

Footnotes
^aIdentified via cross‐referencing.
^bThe synopsis is about a German extension phase of the study.
 

eTable 3. EU Clinical Trials Register

Foonotes

^aIdentified via cross‐referencing.
^bPDF‐file of data from ClinicalTrials.gov.
^cEarlier version of the included synopsis from BfArM.
 

eTable 4. ISRCTN

Footnote

^aIdentified via cross referencing.

eTable 5. Pharmaceutical company databases

Footnotes

For YODA, we counted the trial entries and available documents as separate records in our flowchart. For Novartis, we only counted the included documents in our flowchart.

^aIdentical to document from EU Clinical Trials Register, therefore not included.
^bSimilar to the document from BfArM (but without the amendments), therefore not included.
^cThe Yale University Open Data Access (YODA) declined two of our requests. The Weisler 2009 trial was sponsored by Janssen and compared bavisant, a histamine antagonist, with placebo, OROS methylphenidate and atomoxetine. Our request was declined because bavisant has been out‐licensed to another company. Chronis‐Tuscano 2004 lists McNeil as sponsor in the published report, and as collaborator and sponsor in the Clinicaltrials.Gov entry. We were not granted access to data with the argument that Johnson & Johnson is not the data holder.
^dMade available upon our request.

eTable 6. National guidelines and other systematic reviews

One author (KB) handsearched two national guidelines (Sundhedsstyrelsen 2017; NICE 2018), as prespecified in our protocol (Boesen 2017b), and the two most recently published systematic reviews (Cortese 2018; Elliott 2020). It yielded three additional records, and three references were not obtainable.

eTable 7. Cross referenced records

 Footnotes

CSR = Clinical Study Report; NiH = National Institute of Health Research Portfolio Online Reporting Tools

^aTrial entries or separately linked documents.
^bGerman extension study.

Drug regulatory databases

See the full search results in the additional datafile available on OSF (osf.io/39wzk/?view_only=a1d2c58b069c4e99b8c836107e99fcad).

eTable 8. Drug regulatory documents

Footnotes:
^aThis was a BfArM Public Assessment Report of Medikinet in German. We did not find this record in our systematic search of the BfArM database, but as a reference in an Arzneitelegramm (www.arznei-telegramm.de/html/2011_10/1110085_01.html).
^bOnly harms data from Casas 2008 were included.
^cAlmost identical to document from EUCTR.
^eOne collated document, consisting of one CSR Synopsis and a part Clinical Trial Report (the full report was found on EUCTR).

eTable 9. Overview of author correspondence

eTable 10. Specification of serious adverse events

Footnotes

^aThe 15 trials reporting serious adverse events for at least one group.
^bReported in FDA (Food and Drug Administration) Medical Review, p 19. The three other events occurred in extension phase.
^c'Aggression and delusion of reference' was not listed as a serious adverse event.
^d'Abnormal thinking" was not listed as a serious adverse event.
^eReported for the two methylphenidate and placebo groups together at 52 weeks follow‐up.
^fReported in conference proceeding, but not for placebo group.
^gData according to ClinicalTrials.gov.
^hThe pericarditis event in the placebo group occurred after study completion, but it was not reported when exactly. In comparison, the aneurism event in Huss 2010 (see below), was not included since it occurred after study completion.
ⁱWe noted that one death (in the methylphenidate group) due to aortic dissection rupture 21 days after study completion was not reported as a serious adverse event (Huss 2010; Huss et al. 2014, p 56).
^jThere were important differences between reported serious adverse events in Health Canada’s Product Information, FDA’s Medical Review and on ClinicalTrials.gov. We used the ClinialTrials.gov results.

eTable 11. Serious adverse events or severe psychiatric adverse events

eTable 12. Dose reductions due to psychiatric adverse events

eTable 13. Dropouts due to psychiatric adverse events